WHAT IS CLAIMED:

1. An oral dosage form comprising (a) mirdametinib having a d90 no more than 250 microns and (b) one or more pharmaceutically acceptable excipients.

2. The oral dosage form of claim 1, wherein the mirdametinib has a d50 of no more than 50 microns.

3. The oral dosage form of claim 1, wherein the mirdametinib has a d50 of no more than 30 microns.

4. The oral dosage form of claim 1, wherein the dosage form is a capsule prepared by (i) roller compaction of a blend of the mirdametinib and one or more pharmaceutically acceptable excipients and (ii) encapsulating the compacted blend into a capsule.

5. An oral dosage form comprising (a) 1 mg mirdametinib having a d90 no more than 250 microns and (b) one or more pharmaceutically acceptable excipients, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, an $AUC_{0\text{-}12h}$ less than 400 ng·h/mL, a C_{max} no more than 40 ng/mL, or both.

6. The oral dosage form of claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, an $AUC_{0\text{-}12h}$ less than 200 ng·h/mL.

7. The oral dosage form of claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, $AUC_{0\text{-}12h}$ less than 100 ng·h/mL.

8. The oral dosage form of claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, a C_{max} no more than 32 ng/mL.

9. The oral dosage form of claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, a C_{max} no more than 30 ng/mL.

10. The oral dosage form of claim 1, wherein the dosage form is a capsule.

11. The oral dosage form of claim 1, wherein the dosage form is a tablet.

12. The oral dosage form of claim 11, wherein the dosage form is a dispersible tablet.

13. Use of an oral dosage form of claim 1 in the manufacture of a medicament for the treatment of neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) in a human patient, wherein the oral dosage form is to be administered orally.

14. The use of claim 13, wherein about 2 mg/m^2 mirdametinib is to be administered to the patient twice daily.

15. The use of claim 13, wherein

(a) for a patient having a body surface area no more than 0.69 m^2, the patient is initially to be administered 1 mg mirdametinib twice daily,

(b) for a patient having a body surface area of 0.7 to 1.04 m^2, the patient is initially to be administered 2 mg mirdametinib twice daily,

(c) for a patient having a body surface area of 1.05 to 1.49 m^2, the patient is initially to be administered 3 mg mirdametinib twice daily, and

(d) for a patient having a body surface area of at least 1.5 m^2, the patient is initially to be administered 4 mg mirdametinib twice daily.

16. The use of claim 13, wherein

(a) for a patient having a body surface area of 0.4 to 0.59 m^2, the patient is initially to be administered 1 mg mirdametinib twice daily,

(b) for a patient having a body surface area of 0.6 to 0.79 m^2, the patient is

initially to be administered 1.5 mg mirdametinib twice daily,

(c) for a patient having a body surface area of 0.8 to 0.99 m^2, the patient is initially to be administered 2 mg mirdametinib twice daily,

(d) for a patient having a body surface area of 1.0 to 1.19 m^2, the patient is initially to be administered 2.5 mg mirdametinib twice daily,

(e) for a patient having a body surface area of 1.2 to 1.39 m^2, the patient is initially to be administered 3 mg mirdametinib twice daily,

(f) for a patient having a body surface area of 1.4 to 1.59 m^2, the patient is initially to be administered 3.5 mg mirdametinib twice daily, and

(g) for a patient having a body surface area of at least 1.6 m^2, the patient is initially to be administered 4 mg mirdametinib twice daily.

17. The use of claim 16, wherein the patient is less than 12 years of age.

18. The use of claim 16, wherein the mirdametinib is to be administered in the form of one or more 0.5 mg tablets, one or more 1 mg tablets, or any combination of any of the foregoing.

19. The use of claim 16, wherein the mirdametinib is to be administered in the form of one or more dispersible tablets.

20. The use of claim 13, wherein

(a) for a patient having a body surface area of 0.4 to 0.69 m^2, the patient is initially to be administered 1 mg mirdametinib twice daily,

(b) for a patient having a body surface area of 0.7 to 1.04 m^2, the patient is initially to be administered 2 mg mirdametinib twice daily,

(c) for a patient having a body surface area of 1.05 to 1.49 m^2, the patient is initially to be administered 3 mg mirdametinib twice daily, and

(d) for a patient having a body surface area of at least 1.5 m^2, the patient is initially to be administered 4 mg mirdametinib twice daily.

21. The use of claim 20, wherein the patient is at least 12 years of age.

22. The use of claim 20, wherein the mirdametinib is to be administered in the form of one or more capsules.

23. The use of claim 13, wherein

(a) for a patient having a body surface area of 0.4 to 0.59 m^2, the patient is initially to be administered 1 mg mirdametinib twice daily,

(b) for a patient having a body surface area of 0.6 to 0.79 m^2, the patient is initially to be administered 1.5 mg mirdametinib twice daily,

(c) for a patient having a body surface area of 0.8 to 0.99 m^2, the patient is initially to be administered 2 mg mirdametinib twice daily,

(d) for a patient having a body surface area of 1.0 to 1.39 m^2, the patient is initially to be administered 2.5 mg mirdametinib twice daily,

(e) for a patient having a body surface area of 1.4 to 1.59 m^2, the patient is initially to be administered 3 mg mirdametinib twice daily,

(f) for a patient having a body surface area of 1.6 to 1.69 m^2, the patient is initially to be administered 3.5 mg mirdametinib twice daily, and

(g) for a patient having a body surface area of at least 1.7 m^2, the patient is initially to be administered 4 mg mirdametinib twice daily.

24. The use of claim 23, wherein the patient is less than 12 years of age.

25. The use of claim 23, wherein the mirdametinib is to be administered in the form of one or more 0.5 mg tablets, one or more 1 mg tablets, or any combination of any of the foregoing.

26. The use of claim 23, wherein the mirdametinib is to be administered in the form of one or more dispersible tablets.

27. The use of claim 13, wherein the use further comprises prior to treatment (i) determining whether to select mirdametinib as a treatment for the patient, and (ii) selecting mirdametinib as a treatment for the patient at least partially based on its objective response rate, where the objective response rate is defined as at least a 20% decrease in tumor size using centrally read MRI volumetric analysis.

28. The use of claim 27, wherein in step (i), mirdametinib is selected based on a response rate of at least 70%.

29. The use of claim 13, wherein the mirdametinib is in the form of one or more dispersible tablets, and prior to administration, the one or more dispersible tablets are to be dispersed in water to form a suspension and optionally the suspension is swirled until no lumps remain.

30. The use of claim 13, wherein each of the one or more oral dosage forms is a capsule prepared by (i) roller compaction of a blend of the mirdametinib and one or more pharmaceutically acceptable excipients and (ii) encapsulating the compacted blend into a capsule.